Breaking News

Large insurer to cover mental health digital therapeutics; FDA panel votes for withdrawal of controversial premature birth medication 

  

 

Daily Recap

STAT+: Large insurer's decision to cover some prescription digital therapies may be a milestone for app makers

By Mario Aguilar

Tony Webster/Creative Commons

Pittsburgh-based Highmark quietly put in place a policy in August describing when these treatments may be “medically necessary.”

Read More

STAT+: FDA panel votes that a controversial premature birth medication should be withdrawn

By Ed Silverman

Adobe

The highly unusual hearing was closely watched because it was seen as a test of the ability of the FDA to exercise its authority.

Read More

Opinion: What the Makena vote means about accelerated approval, trust, and the FDA

By Mikkael A. Sekeres

Sarah Silbiger/Getty Images

The vote to pull Makena off the market is the right decision. But the FDA needs to better communicate why some drugs deserve this.

Read More

Black Death may have influenced evolution of genes involved in immune responses, study finds

By Brittany Trang

Researchers found the Black Death may have contributed to humans' current susceptibility to autoimmune diseases like Crohn's disease.

Read More

Opinion: To learn lessons from pandemics, don't listen to big pharma

By Winnie Byanyima

Rafiq Maqbool/AP

With empty pledges of "equity" and "global solidarity," the Berlin Declaration does little to help the Global South fight pandemics.

Read More

FDA authorizes booster shot for Novavax's Covid-19 vaccine

By Helen Branswell

JUSTIN TALLIS/AFP via Getty Images

Unlike the latest boosters from Pfizer-BioNTech and Moderna, the Novavax booster only targets the original strain of SARS-CoV-2.

Read More

Wednesday, October 19, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments